Next Generation Sequencing Testing (NGS)

NHS BLOOD AND TRANSPLANT

There is 1 contract in this contracting process.

Summary of the contracting process

NHS Blood and Transplant, operating under the central government, is in the initial planning stages of a public procurement process for "Next Generation Sequencing Testing (NGS)". This process is primarily aimed at their Cellular and Molecular Therapies directorate and involves quality control testing for products related to advanced therapeutic investigational medicinal products. Situated in Bristol, the buying authority requires services in system quality assurance within the postcode region UKK11. An engaged market exercise is scheduled with a deadline for interest set for 13th June 2025, and a supplier meeting anticipated the following week. The anticipated contract period could begin on 1st October 2025 and potentially extend through to 30th September 2027. Future communication is expected around 17th July 2025.

This tender presents a significant prospect for businesses adept in quality assurance and testing services, particularly those capable of fulfilling stringent regulatory requirements. Providers specialising in sophisticated biotechnology testing or advanced quality control services would find this opportunity beneficial for growth. The potential contract value is substantial at £300,000, with an overall gross potential of £360,000, implying a lucrative chance for firms that can deliver high-quality and precise testing solutions. Engaging early in the market engagement exercise allows businesses to influence procurement outcomes and demonstrate their capabilities, setting the stage for future collaboration with a prominent public sector entity such as NHS Blood and Transplant.

This is an AI-generated summary 🚀

How useful is this summary?

Planning

Next Generation Sequencing Testing (NGS)

NHS BLOOD AND TRANSPLANT

Contract Timeline

Publication Date

15th May 2025 15:45:07 PM

Planning Deadline

13th June 2025 22:59:59 PM Expired
Contract Summary

NHS Blood and Transplant (NHSBT) are seeking a provider for Next Generation Sequencing (NGS) QC testing requirements for the Cellular and Molecular Therapies (CMT) directorate, namely the Clinical Biotechnology Centre (CBC). CBC handle a number of products in the production of Advanced Therapeutic Investigational Medicinal Products (ATMPs) and starter material master cell banks (MCBs). These require NGS QC testing services that meet specific regulatory requirements.
Contract Details

Open Contracting ID

ocds-h6vhtk-0514f8

Publication Source

Find a Tender Service

Procurement Stage

Planning

Procurement Method

N/A

Procurement Method Details

N/A

Procurement Category

Services

Tender Suitability

Framework / DPS
Contract Classification

CPV Code(s)

CPV Division(s)
Awarding Authority

NHS BLOOD AND TRANSPLANT

Buyer Name

Buyer Email

rowena.thomas@nhsbt.nhs.uk

Buyer Phone

Buyer Address

500 North Bristol Park

Bristol

BS34 7QH

United Kingdom

View contract on Find a Tender Service

Next Generation Sequencing Testing (NGS)

NHS BLOOD AND TRANSPLANT

Contract Timeline

Contract Summary

Contract Details

Contract Classification

Awarding Authority